Replimune Group (NASDAQ:REPL) Stock: Insider Joseph Slattery Sells 5,200 Shares

Replimune Group, Inc. (NASDAQ:REPL) Director Joseph Slattery sold 5,200 shares of the stock in a transaction on Monday, November 9th. The stock was sold at an average price of $21.80, for a total value of $113,360.00. Following the sale, the director owned 1,467 shares of the company’s stock, valued at approximately $31,980.60. This represents a 78.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Replimune Group Stock Up 4.6%

REPL traded up $1.02 during trading on Tuesday, reaching $23.28. 3,017,307 shares of the stock traded hands, compared to its average volume of 4,324,637. The stock’s 50-day simple moving average is $14.23 and its two-hundred day simple moving average is $9.75. The company has a debt-to-equity ratio of 0.59, a current ratio of 7.11 and a quick ratio of 6.90. Replimune Group, Inc. has a fifty-two week low of $1.50 and a fifty-two week high of $23.41. The stock has a market cap of $2.21 billion, a price-to-earnings ratio of -8.34 and a beta of 0.93.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings results on Wednesday, October 28th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.24. As a group, equities research analysts expect that Replimune Group, Inc. will post -2.40 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Quantinno Capital Management LP boosted its stake in Replimune Group by 782.7% during the first quarter. Quantinno Capital Management LP now owns 108,477 shares of the company’s stock worth $830,000 after buying an additional 96,188 shares in the last quarter. Montanova Capital LLC lifted its stake in Replimune Group by 4.0% during the second quarter. Montanova Capital LLC now owns 4,389,836 shares of the company’s stock worth $48,595,000 after purchasing an additional 168,000 shares during the period. Seven Fleet Capital Management LP acquired a new stake in Replimune Group during the first quarter valued at approximately $921,000. Squarepoint Ops LLC bought a new stake in shares of Replimune Group in the 2nd quarter valued at approximately $1,454,000. Finally, Deutsche Bank AG bought a new stake in shares of Replimune Group in the 2nd quarter valued at approximately $857,000. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on REPL shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Replimune Group in a research note on Monday, October 5th. Wall Street Zen raised shares of Replimune Group from a “sell” rating to a “hold” rating in a research report on Saturday, October 31st. Weiss Ratings restated a “sell (e+)” rating on shares of Replimune Group in a report on Wednesday, November 4th. JPMorgan Chase & Co. boosted their price target on Replimune Group from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 26th. Finally, Wolfe Research upgraded Replimune Group to an “outperform” rating in a research note on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Replimune Group has an average rating of “Moderate Buy” and a consensus price target of $14.33.

About Replimune Group

Replimune Group is a biotechnology company focused on developing tumor-directed immunotherapies for people with cancer. Its proprietary platform uses genetically modified herpes simplex viruses, designed to be injected into tumors and stimulate an immune response against cancer. The company’s investigational pipeline includes RP1, an engineered oncolytic virus that expresses proteins intended to promote tumor cell destruction and immune activation. Replimune is also developing other candidates that combine virus-based treatment with additional immune-stimulating approaches.